Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HCP1803-4 in Essential Hypertension
NCT07660796Phase 3Not yet recruiting
- Sponsor
- Hanmi Pharmaceutical
- Start
- Jul 2026
- Primary completion
- Oct 2027
- Countries
- 1
01
Overview
A Phase 3 trial of amlodipine + losartan + chlorthalidone in essential hypertension, sponsored by Hanmi Pharmaceutical. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
amlodipine + losartan + chlorthalidone
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT07660796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07660796.